These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9859750)

  • 1. A statistical consideration of CLAU-S: a disease specific questionnaire for the assessment of quality of life in patients with intermittent claudication.
    Spengel FA; Lehert P; Dietze S
    Vasa; 1998 Nov; 27(4):253. PubMed ID: 9859750
    [No Abstract]   [Full Text] [Related]  

  • 2. Naftidrofuryl in quality of life (NIQOL). A Belgian study.
    D'Hooge D; Lehert P; Clement DL
    Int Angiol; 2001 Dec; 20(4):288-94. PubMed ID: 11782694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intermittent claudication and quality of life. Psychometric validation of the French version of the CLAU-S questionnaire].
    Boccalon H; Lehert P; Comte S
    J Mal Vasc; 2000 Apr; 25(2):98-107. PubMed ID: 10804390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication.
    Spengel F; Brown TM; Poth J; Lehert P
    Vasa; 1999 Aug; 28(3):207-12. PubMed ID: 10483329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of the quality of life of patients with peripheral vascular diseases].
    Wohlgemuth WA; Niechzial M; Nagel E; Bohndorf K
    Rofo; 2003 Feb; 175(2):169-75. PubMed ID: 12584614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evidence-based therapy of intermittent claudication].
    Krankenpfl J; 2004; 42(5-6):184. PubMed ID: 15527244
    [No Abstract]   [Full Text] [Related]  

  • 7. Naftidrofuryl: a review of its use in the treatment of intermittent claudication.
    Goldsmith DR; Wellington K
    Drugs Aging; 2005; 22(11):967-77. PubMed ID: 16323973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Double-blind randomized comparative study of nicergoline naftidrofuryl on the quality of life in chronic obliterative arteriopathy of lower limbs with intermittent claudication].
    Meilhac B; Montestruc F; Aubin F; Djian F; Rouffy J
    Therapie; 1997; 52(3):179-86. PubMed ID: 9366101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The antagonist of type-II serotonin receptors naftidrofuryl in the treatment of patients with intermittent claudication].
    Komarov AL; Panchenko EP; Eshkeeva AR; Dobrovol'skiĭ AB; Titaeva EV; Karpov IuA
    Ter Arkh; 1996; 68(2):49-53. PubMed ID: 8771659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
    Roset PN
    Br J Surg; 2013 Dec; 100(13):1838. PubMed ID: 24227374
    [No Abstract]   [Full Text] [Related]  

  • 11. Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
    Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
    Br J Surg; 2013 Dec; 100(13):1838-9. PubMed ID: 24227373
    [No Abstract]   [Full Text] [Related]  

  • 12. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program.
    Spengel F; Clément D; Boccalon H; Liard F; Brown T; Lehert P
    Int Angiol; 2002 Mar; 21(1):20-7. PubMed ID: 11941270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International validation of the CLAU-S quality-of-life questionnaire for use in patients with intermittent claudication.
    Marquis P; Comte S; Lehert P
    Pharmacoeconomics; 2001; 19(6):667-77. PubMed ID: 11456214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new questionnaire for assessing the quality of life of patients with intermittent claudication].
    Silvestro A; Bacchieri A; Bucur R; Di Donato AM; Costantino C; Corrado S; Brevetti G
    Minerva Cardioangiol; 2000 Dec; 48(12):455-65. PubMed ID: 11253331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug therapy of intermittent claudication in the IIb stage of arterial occlusive disease].
    Kriessmann A; Neiss A; Lutilsky L; Beermann M; Kramann B
    Med Welt; 1979 Jun; 30(23):888-91. PubMed ID: 459805
    [No Abstract]   [Full Text] [Related]  

  • 17. [Naftidrofuryl in the therapy of chronic arterial occlusive disease in the intermittent claudication stage].
    Valentin A; Karnik R; Stöllberger C; Slany J
    Vasa Suppl; 1987; 20():361-4. PubMed ID: 3321493
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical effectiveness of naftidrofuryl in intermittent claudication].
    Kriessmann A; Neiss A
    Vasa Suppl; 1988; 24():27-32. PubMed ID: 3062823
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Mehta T, Venkata Subramaniam A, Chetter I, McCollum P. Assessing the validity and responsiveness of disease-specific quality of life instruments in intermittent claudication. Eur J Vasc Endovasc Surg 2006;31:46-52.
    Chong PF; Garratt AM; Greenhalgh RM; Davies AH
    Eur J Vasc Endovasc Surg; 2006 Jul; 32(1):110-1; author reply 110. PubMed ID: 16584901
    [No Abstract]   [Full Text] [Related]  

  • 20. Disease-specific quality of life assessment in intermittent claudication: review.
    Mehta T; Venkata Subramaniam A; Chetter I; McCollum P
    Eur J Vasc Endovasc Surg; 2003 Mar; 25(3):202-8. PubMed ID: 12623330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.